Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
31 October 2023
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine", or the "Company")
Steriwave use expanded following successful pilot
· Alberta Health Services has expanded its use of Steriwave nasal photodisinfection to reduce the incidence of surgical site infections (SSIs) in orthopedic surgery following a successful pilot at the Mazankowski Alberta Heart Institute.
· SSIs, the most common of healthcare-associated infections (HAIs), are a significant burden to healthcare systems as well as to patients, with the estimated cost of a prosthetic hip or knee infection ranging from C$31,000 to more than C$100,000.[1]
Ondine Biomedical Inc (AIM: OBI), the Canadian life sciences company developing non-antibiotic photodisinfection therapies to prevent and treat healthcare-associated and drug-resistant infections announces that Alberta Health Services has confirmed that it is expanding its use of Ondine's Steriwave® nasal photodisinfection following early data from its pilot introduction at the Mazankowski Alberta Heart Institute, which saw significant reductions in surgical site infections following cardiac surgery. The Royal Alexandra Hospital in Edmonton, Canada, will use Steriwave nasal photodisinfection prior to its c. 3,000 orthopedic surgeries over the next year.
Ondine has pioneered nasal photodisinfection as a rapid, non-antibiotic method for decolonizing the nose of the pathogens carried by patients that can lead to HAIs. Steriwave uses a proprietary red light-activated agent to eliminate infection-causing bacteria, viruses, and fungi in the nose, a major reservoir of germs[2], without causing resistance. At the Mazankowski Alberta Heart Institute, Steriwave replaced the previous standard of care, the antibiotic mupirocin. Mupirocin is commonly used for nasal decolonization to prevent SSIs, but has poor rates of patient compliance and reported resistance rates as high as 81%.[3]
Ondine Biomedical's CEO Carolyn Cross said:
"We are very pleased to be collaborating with Alberta Health Services to reduce the incidence of SSIs in Alberta without generating antibiotic resistance. The successful initial implementation of Steriwave into the pre-surgical treatment protocols at the Mazankowski Alberta Heart Institute has driven rapid adoption of Steriwave for orthopedic surgeries at the Royal Alexandra Hospital.
"The rising rate of antimicrobial resistance (AMR) makes it more important than ever to have cost-effective, non-antibiotic methods for preventing HAIs. Alongside growing global concerns about the consequences of AMR, we are seeing more hospitals looking to move away from topical antibiotic nasal decolonization. In addition to growing resistance, topical antibiotics require patient compliance with twice daily treatments for five days to achieve efficacy on a limited number of bacterial species as compared to five minutes for photodisinfection to eradicate a broad spectrum of bacteria, viruses and fungi just
Antimicrobial Photodynamic Therapy Against Extensively Drug-Resistant (XDR) Gram Negative Isolates With Novel Antibiotic Resistance Factors", will be presented at IP2023 between 1:10pm and 2:40pm (BST) on 18 October 2023. A further announcement providing more details of the research will be released by the Company concurrent with the start of the presentation.
Have you not read the RNS or just upset that you have no money left to invest
Steriwave shown to reduce resistant bacteria by >99.9%
· New research presented by Ondine shows that Steriwave photodisinfection reduces antibiotic-resistant bacteria by more than 99.9% without generating resistance.
· The research suggests that photodisinfection is a viable alternative to antibiotics.